Feiya Ou

Program: Immunology

Current advisor: Kenneth M. Murphy, MD, PhD

Undergraduate university: Xiamen University, 2019

Enrollment year: 2019

Research summary
Molecular circuits and circuitries controlling dendritic cell development

Graduate publications
Kim S, Chen J, Ou F, Liu TT, Jo S, Gillanders WE, Murphy TL, Murphy KM. 2024 Transcription factor C/EBPα is required for the development of Ly6Chi monocytes but not Ly6Clo monocytes. Proc Natl Acad Sci USA, 121(15):e2315659121. PMCID: PMC11009651

Ou F, Liu TT, Desai P, Ferris ST, Kim S, Shen H, Ohara RA, Jo S, Chen J, Postoak JL, Du S, Diamond MS, Murphy TL, Murphy KM. 2024 Optimization of the Irf8 +32-kb enhancer disrupts dendritic cell lineage segregation. Nat Immunol, 25(11):2043-56. PMCID:

Ferris ST, Liu T, Chen J, Ohara RA, Ou F, Wu R, Kim S, Murphy TL, Murphy KM. 2023 WDFY4 deficiency in NOD mice ameliorates autoimmune diabetes and insulitis. Proc Natl Acad Sci USA, 120(13):e2219956120. PMCID: PMC10068798

Liu TT, Ou F, Belk JA, Bagadia P, Anderson DA 3rd, Durai V, Yao W, Satpathy AT, Murphy TL, Murphy KM. 2023 Cis interactions in the Irf8 locus regulate stage-dependent enhancer activation. Genes Dev, 37(7-8):291-302. PMCID: PMC10153461

Ou F, Ferris ST, Kim S, Wu R, Anderson DA 3rd, Liu TT, Jo S, Chen MY, Gillanders WE, Murphy TL, Murphy KM. 2023 Enhanced in vitro type 1 conventional dendritic cell generation via the recruitment of hematopoietic stem cells and early progenitors by Kit ligand. Eur J Immunol, 53(9)::e2250201. PMCID: PMC11040600

Kim S, Chen J, Jo S, Ou F, Ferris ST, Liu TT, Ohara RA, Anderson DA, Wu R, Chen MY, Gillanders WE, Gillanders WE, Murphy TL, Murphy KM. 2023 IL-6 selectively suppresses cDC1 specification via C/EBPβ. J Exp Med, 220(10):e20221757. PMCID: PMC10336151

Anderson DA, Ou F, Kim S, Murphy TL, Murphy KM. 2022 Transition from cMyc to L-Myc during dendritic cell development coordinated by rising levels of IRF8. J Exp Med, 219(2):e20211483. PMCID: PMC8713298

Ferris ST, Ohara RA, Ou F, Wu R, Huang X, Kim S, Chen J, Liu TT, Schreiber RD, Murphy TL, Murphy KM. 2022 cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol Res, 10(8):920-931

Liu TT, Kim S, Desai P, Kim DH, Huang X, Ferris ST, Wu R, Ou F, Egawa T, Van Dyken SJ, Diamond MS, Johnson PF, Kubo M, Murphy TL, Murphy KM. 2022 Ablation of cDC2 development by triple mutations within the Zeb2 enhancer. Nature, 607(7917):142-48. PMCID:

Wu R, Ohara RA, Jo S, Liu TT, Ferris ST, Ou F, Kim S, Theisen DJ, Anderson DA 3rd, Wong BW, Gershon T, Schreiber RD, Murphy TL, Murphy KM. 2022 Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat Immunol, 23(11):1536-50. PMCID: PMC9896965